Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00058812 | Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts | ||
| NCT02276820 | Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) | ||
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma | ||
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | ||
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | ||
| NCT02108522 | Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant | ||
| NCT01611298 | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | ||
| NCT00057005 | Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | ||
| NCT00078533 | Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant | ||
| NCT00040482 | High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis | ||
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | ||
| NCT00058604 | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | ||
| NCT01570283 | ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus | ||
| NCT01247688 | Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies | ||
| NCT03093350 | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer | ||
| NCT01189786 | Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection | ||
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | ||
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | ||
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | ||
| NCT00058591 | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | ||
| NCT00880789 | Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus | ||
| NCT00950846 | Umbilical Cord Blood Transplant for Congenital Pediatric Disorders | ||
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | ||
| NCT03081910 | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | ||
| NCT01953900 | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma | ||
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | ||
| NCT01702961 | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | ||
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) | ||
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | ||
| NCT00078546 | EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) | ||
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | ||
| NCT02065362 | TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | ||
| NCT00590083 | Administration of Virus-Specific Cytotoxic T-Lymphocytes | ||
| NCT01192555 | Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT00082225 | LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) | ||
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | ||
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | ||
| NCT00056966 | Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases | ||
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | ||
| NCT03478215 | Mesenchymal Stromal Cells in Living Donor Kidney Transplantation | ||
| NCT01333046 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | ||
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | ||
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | ||
| NCT00062855 | Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma | ||
| NCT00040469 | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | ||
| NCT00889954 | Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy |
